Bg pattern

IBIS 10 mg ORALLY DISPERSIBLE TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use IBIS 10 mg ORALLY DISPERSIBLE TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Patient Information Leaflet

Ibis 10 mg orodispersible tablets

Bilastine

For children from2 to 11 years with a minimum body weight of 15 kg

Read this leaflet carefully before your child starts taking this medicine, as it contains important information for you.

  • Keep this leaflet, as you may need to read it again.

If you have any questions, ask your doctor or pharmacist.

  • This medicine has been prescribed to your child only, and you should not give it to others, even if they have the same symptoms as your child, as it may harm them.
    • If your child experiences side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.

Contents of the pack

  1. What Ibis is and what it is used for
  2. What you need to know before taking Ibis
  3. How to take Ibis
  4. Possible side effects
  5. Storage of Ibis
  6. Contents of the pack and further information

1. What Ibis is and what it is used for

Ibis contains bilastine as the active substance, which is an antihistamine. Ibis is used to relieve the symptoms of allergic rhinoconjunctivitis (sneezing, nasal itching, nasal discharge, nasal congestion, and red and itchy eyes) and other forms of allergic rhinitis. It can also be used to treat itchy skin eruptions (hives or urticaria).

Ibis 10 mg orodispersible tablets are indicated in children from 2 to 11 years of age with a minimum body weight of 15 kg.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before taking Ibis

Do not take Ibis:

  • if your child is allergic to bilastine or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor or pharmacist before starting to take Ibis if your child has moderate or severe kidney or liver impairment, low blood levels of potassium, magnesium, or calcium, if your child has or has had heart rhythm problems or if their heart rate is very low, if your child is taking medicines that may affect the heart rhythm, if your child has or has had a certain abnormal heart rhythm pattern (known as QTc interval prolongation in the electrocardiogram) that may occur in some types of heart disease, or if your child is taking other medicines (see "Using Ibis with other medicines").

Children

Do not give this medicine to children under 2 years of age or with a body weight below 15 kg, as there is not enough data available.

Using Ibis with other medicines

Tell your doctor or pharmacist if your child is using, has recently used, or might use any other medicines, including those obtained without a prescription.

Some medicines should not be taken together, and others may require a dose adjustment when taken together.

Always tell your doctor or pharmacist if your child is taking or receiving any of the following medicines in addition to Ibis:

  • Ketoconazole (an antifungal medicine)
  • Erythromycin (an antibiotic)
  • Diltiazem (for treating angina pectoris - chest pain or pressure)
  • Ciclosporin (to reduce the activity of the immune system, and thus prevent transplant rejection or reduce disease activity in autoimmune and allergic disorders, such as psoriasis, atopic dermatitis, or rheumatoid arthritis)
  • Ritonavir (for treating HIV)
  • Rifampicin (an antibiotic)

Taking Ibis with food, drinks, and alcohol

These orodispersible tablets should notbe taken with food or withgrapefruit juice or other fruit juices, as this would decrease the effect of bilastine. To avoid this, you can:

  • give your child the orodispersible tablet and wait for one hour before your child eats or takes fruit juices, or
  • if your child has taken food or fruit juices, wait for two hours before giving the orodispersible tablet.

Bilastine, at the recommended dose in adults (20 mg), does not increase the sleepiness caused by alcohol.

Pregnancy, breastfeeding, and fertility

This medicine is for use in children from 2 to 11 years of age with a minimum body weight of 15 kg. However, the following information on the safe use of this medicine should be taken into account. There are no data or limited data available on the use of bilastine in pregnant or breastfeeding women and on its effects on fertility.

If you are pregnant or breastfeeding, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Consult your doctor or pharmacist before taking any medicine.

Driving and using machines

It has been shown that bilastine 20 mg does not affect performance during driving in adults. However, each patient's response to the medicine may be different. Therefore, check how this medicine affects your child before they ride a bicycle or other vehicles or operate machinery.

Ibis contains ethanol and sodium

This medicine contains 0.0015 mg of alcohol (ethanol) per orodispersible tablet, equivalent to 1 mg/100 g (0.001% w/w). The amount in one orodispersible tablet is equivalent to less than 0.00004 ml of beer or 0.00002 ml of wine.

The small amount of alcohol in this medicine does not produce any noticeable effect.

This medicine contains less than 1 mmol of sodium (23 mg) per orodispersible tablet; this is essentially "sodium-free".

3. How to take Ibis

Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.

Use in children

The recommended dose in children from 2 to 11 years of age with a minimum body weight of 15 kg is 10 mg of bilastine (1 orodispersible tablet) once daily for the symptomatic relief of allergic rhinoconjunctivitis and urticaria.

Do not give this medicine to children under 2 years of age or with a body weight below 15 kg, as there is not enough data available.

For adults, including elderly patients and adolescents from 12 years of age, the recommended dose is 20 mg of bilastine once daily. For this patient population, a more suitable pharmaceutical form - tablets - is available; consult your doctor or pharmacist.

  • The orodispersible tablet is for oral use.
  • Please place the orodispersible tablet in your child's mouth. It will disperse rapidly in the saliva and can then be swallowed easily.
  • Alternatively, you can disperse the orodispersible tablet in a spoonful of water before giving it to your child. This is highly recommended in children under 6 years, as they are prone to choking on tablets. Make sure there are no sediment remains in the spoon.
  • You should use only water for dispersion;do not use grapefruit juice or any other fruit juice.
  • You should give the orodispersible tablet to your child one hour before or two hours after they have taken any food or fruit juice.

The duration of treatment depends on your child's underlying disease, and your doctor will determine how long they should take Ibis.

If your child takes more Ibis than they should

If your child, or anyone else, exceeds the dose of this medicine, inform your doctor immediately or go to the casualty department of the nearest hospital. Please remember to take this medicine pack or this leaflet with you.

If your child forgets to take Ibis

If you forget to give your child their daily dose on time, give it to them the same day as soon as you remember. Then, give the next dose the following day at the usual time, as indicated by your doctor.

Never give a double dose to make up for a forgotten dose.

If your child stops taking Ibis

In general, no effects will appear after stopping treatment with Ibis.

If you have any other questions about the use of this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If your child experiences allergic reactions whose symptoms may include difficulty breathing, dizziness, collapse, or loss of consciousness, swelling of the face, lips, tongue, or throat, and/or swelling and redness of the skin, stop giving this medicine and go to your doctor immediately.

Other side effects that may appear in children:

Common: may affect up to 1 in 10 people

  • allergic conjunctivitis (eye irritation)
  • headache

Uncommon: may affect up to 1 in 100 people

  • eye irritation
  • dizziness
  • loss of consciousness
  • diarrhea
  • nausea (feeling sick)
  • lip swelling
  • eczema
  • urticaria (hives)
  • fatigue
  • rhinitis (nasal irritation)
  • stomach pain (abdominal pain/upper abdominal pain)

Side effects that may appear in adults and adolescents:

Common: may affect up to 1 in 10 people

  • headache
  • drowsiness

Uncommon: may affect up to 1 in 100 people

  • electrocardiogram changes
  • blood tests showing changes in liver function
  • dizziness
  • stomach pain
  • fatigue
  • increased appetite
  • irregular heartbeat
  • weight gain
  • nausea (feeling sick)
  • anxiety
  • dry or irritated nose
  • abdominal pain
  • diarrhea
  • gastritis (inflammation of the stomach lining)
  • vertigo (a feeling of dizziness or spinning)
  • feeling weak
  • thirst
  • shortness of breath
  • dry mouth
  • indigestion
  • itching
  • cold sore (herpes labialis)
  • fever
  • tinnitus (ringing in the ears)
  • difficulty sleeping
  • blood tests showing changes in kidney function
  • increased blood fats

Frequency not known: cannot be estimated from the available data

  • palpitations (feeling the heartbeat)
  • tachycardia (fast heartbeat)
  • vomiting

Reporting of side effects

If your child experiences any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines and Healthcare Products Agency's (AEMPS) online system: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Ibis

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the pack and blister after EXP. The expiry date is the last day of the month stated.

This medicine does not require any special storage conditions.

Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to a pharmacy, or take it to a designated collection point. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and further information

Composition of Ibis

  • The active substance is bilastine. Each orodispersible tablet contains 10 mg of bilastine.
  • The other ingredients are mannitol (E421), croscarmellose sodium, sodium stearyl fumarate, and sucralose (E955), red grape flavor (main components: gum arabic, ethyl butyrate, triacetin, methyl anthranilate, ethanol, d-limonene, linalool).

Appearance and packaging

Ibis 10 mg orodispersible tablets are round, slightly biconvex, and white, with a diameter of 8 mm.

The tablets are packaged in blisters of 10, 20, 30, or 50 tablets.

Not all pack sizes may be marketed.

Marketing authorization holder

Menarini International Operations Luxembourg, S.A.

1, Avenue de la Gare

L-1611 Luxembourg

Manufacturer

Faes Farma, S.A.

Maximo Agirre Kalea, 14

48940 Leioa (Bizkaia)

Spain

or

A.Menarini Manufacturing Logistics and Services S.r.l.

Campo di Pile

L’Aquila

Italy

You can obtain further information on this medicine from the local representative of the marketing authorization holder:

Laboratorios Menarini, S.A.

Alfons XII, 587 – E 08918 Badalona

(Barcelona) T. +34 934 628 800

E-mail: [email protected]

This medicine is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:

Austria: Nasitop 10 mg Schmelztabletten

Belgium: Bellozal 10 mg orodispersible tablets

Bulgaria: ???????? ?? ???? 10 mg ???????????? ?? ? ?????? ????????

Cyprus: Bilaz 10 mg δισκ?α διασπειρ?μενα στο στ?μα

Czech Republic: Xados

Denmark: Revitelle, smeltetabletter 10 mg

Estonia: Opexa

Finland: Revitelle

France: Bilaska 10 mg comprimé orodispersible

Germany: Bilaxten 10 mg Schmelztabletten

Greece: Bilaz 10 mg δισκ?α διασπειρ?μενα στο στ?μα

Hungary: Lendin

Iceland: Bilaxten 10 mg munndreifitöflur

Ireland: Drynol

Latvia: Opexa 10 mg mute dispergejamas tabletes

Lithuania: Opexa

Luxembourg: Bellozal 10 mg orodispersible tablets

Malta: Gosall 10 mg orodispersible tablets

Norway: Zilas 10 mg smeltetablett

Poland: Clatra

Portugal: Lergonix 10 mg comprimido orodispersível

Romania: Borenar 10 mg comprimate orodispersabile

Slovakia: Omarit 10 mg orodispergovatelné tablety

Slovenia: Bilador 10 mg orodispersibilne tablete

Spain: Ibis 10 mg comprimidos bucodispersables

Sweden: Bilaxten

United Kingdom (Northern Ireland): Ilaxten

Date of last revision of this leaflet:March 2025

Detailed information on this medicine is available on the website of the Spanish Medicines and Healthcare Products Agency (AEMPS) (http://www.aemps.gob.es/)

Online doctors for IBIS 10 mg ORALLY DISPERSIBLE TABLETS

Discuss questions about IBIS 10 mg ORALLY DISPERSIBLE TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for IBIS 10 mg ORALLY DISPERSIBLE TABLETS?
IBIS 10 mg ORALLY DISPERSIBLE TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in IBIS 10 mg ORALLY DISPERSIBLE TABLETS?
The active ingredient in IBIS 10 mg ORALLY DISPERSIBLE TABLETS is bilastine. This information helps identify medicines with the same composition but different brand names.
How much does IBIS 10 mg ORALLY DISPERSIBLE TABLETS cost in pharmacies?
The average pharmacy price for IBIS 10 mg ORALLY DISPERSIBLE TABLETS is around 6.4 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures IBIS 10 mg ORALLY DISPERSIBLE TABLETS?
IBIS 10 mg ORALLY DISPERSIBLE TABLETS is manufactured by Menarini International Operations Luxembourg S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of IBIS 10 mg ORALLY DISPERSIBLE TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether IBIS 10 mg ORALLY DISPERSIBLE TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to IBIS 10 mg ORALLY DISPERSIBLE TABLETS?
Other medicines with the same active substance (bilastine) include ABISAX 20 mg TABLETS, ABRILIA 20 mg TABLETS, ASTRILAX 20 mg TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media